Pancreatic Cancer Research

ResearcherMedical University of WarsawActive in the last 2 years

Marta Magdalena Fudalej

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8665-2875; OpenAlex author ID A5001826770. Sources: OpenAlex.

Their work

Papers
12 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 5 papers · 2026: 3 papers

Papers 12

  1. Can liver-associated parameters serve as prognostic factors in pancreatic cancer? - A retrospective analysis of a large-capacity centre. Co-author DOI 10.1016/j.advms.2026.02.001↗
  2. From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism-A Review. Co-author DOI 10.3390/cancers18060890↗
  3. Comparison of pre-treatment systemic inflammation indices (systemic immune-inflammation index, systemic inflammation response index, and inflammatory benchmark… Co-author DOI 10.5114/wo.2026.159587↗
  4. Inflammation, Immunosuppression, and Immunotherapy in Pancreatic Cancer-Where Are We Now? Co-author DOI 10.3390/cancers17091484↗
  5. The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma: Recent Advancements and Emerging Therapeutic Strategies. Co-author DOI 10.3390/cancers17101599↗
  6. Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients? First author DOI 10.3390/cancers17152453↗
  7. Neoadjuvant Therapy or Upfront Surgery for Pancreatic Cancer-To Whom, When, and How? First author DOI 10.3390/cancers17152584↗
  8. KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities? First author DOI 10.3390/cancers17233769↗
  9. New Treatment Options in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15082327↗
  10. How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated-A Comprehensive Review. First author DOI 10.3390/cancers15174275↗
  11. Quality of Life in Patients with Pancreatic Cancer-A Literature Review. Co-author DOI 10.3390/ijerph20064895↗
  12. Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma-Prevalence, Clinicopathological Variables, and Clinical Outcomes. First author DOI 10.3390/cancers14122840↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anna Maria Badowska-Kozakiewicz · 12 shared papers, 2022–2026 · strength 3.38
  2. Andrzej Deptała · 12 shared papers, 2022–2026 · strength 3.38
  3. Daria Kwaśniewska · 5 shared papers, 2022–2026 · strength 1.29
  4. Kamila Krupa · 4 shared papers, 2025–2026 · strength 1.18
  5. Dominika Mękal · 2 shared papers, 2023–2025 · strength 0.45
  6. Elżbieta Cipora · 2 shared papers, 2023 · strength 0.33
  7. Monika Jarowicz · 1 shared paper, 2026 · strength 0.29
  8. Franciszek Glapiński · 1 shared paper, 2025 · strength 0.27
  9. Remigiusz Kozłowski · 1 shared paper, 2025 · strength 0.27
  10. Marek Durlik · 1 shared paper, 2022 · strength 0.15
  11. Olga Partyka · 1 shared paper, 2023 · strength 0.14
  12. Monika Pajewska · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.